Yan, Ming, Gingras, Marie-Claude, Dunlop, Elaine A. ORCID: https://orcid.org/0000-0002-9209-7561, Nouët, Yann, Dupuy, Fanny, Jalali, Zahra, Possik, Elite, Coull, Barry J., Kharitidi, Dmitri, Dydensborg, Anders Bondo, Faubert, Brandon, Kamps, Miriam, Sabourin, Sylvie, Preston, Rachael S., Davies, David Mark, Roughead, Taren, Chotard, Laëtitia, van Steensel, Maurice A.M., Jones, Russell, Tee, Andrew R. ORCID: https://orcid.org/0000-0002-5577-4631 and Pause, Arnim 2014. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. Journal of Clinical Investigation 124 (6) , pp. 2640-2650. 10.1172/JCI71749 |
Abstract
The Warburg effect is a tumorigenic metabolic adaptation process characterized by augmented aerobic glycolysis, which enhances cellular bioenergetics. In normal cells, energy homeostasis is controlled by AMPK; however, its role in cancer is not understood, as both AMPK-dependent tumor-promoting and -inhibiting functions were reported. Upon stress, energy levels are maintained by increased mitochondrial biogenesis and glycolysis, controlled by transcriptional coactivator PGC-1α and HIF, respectively. In normoxia, AMPK induces PGC-1α, but how HIF is activated is unclear. Germline mutations in the gene encoding the tumor suppressor folliculin (FLCN) lead to Birt-Hogg-Dubé (BHD) syndrome, which is associated with an increased cancer risk. FLCN was identified as an AMPK binding partner, and we evaluated its role with respect to AMPK-dependent energy functions. We revealed that loss of FLCN constitutively activates AMPK, resulting in PGC-1α–mediated mitochondrial biogenesis and increased ROS production. ROS induced HIF transcriptional activity and drove Warburg metabolic reprogramming, coupling AMPK-dependent mitochondrial biogenesis to HIF-dependent metabolic changes. This reprogramming stimulated cellular bioenergetics and conferred a HIF-dependent tumorigenic advantage in FLCN-negative cancer cells. Moreover, this pathway is conserved in a BHD-derived tumor. These results indicate that FLCN inhibits tumorigenesis by preventing AMPK-dependent HIF activation and the subsequent Warburg metabolic transformation.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Subjects: | R Medicine > R Medicine (General) |
Additional Information: | PDF uploaded in accordance with publisher's policies at http://www.sherpa.ac.uk/romeo/issn/0021-9738/ (accessed 1.4.16). |
Publisher: | American Society for Clinical Investigation |
ISSN: | 0021-9738 |
Date of First Compliant Deposit: | 1 April 2016 |
Last Modified: | 06 May 2023 02:11 |
URI: | https://orca.cardiff.ac.uk/id/eprint/79568 |
Citation Data
Cited 100 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |